After its drug Palifosfamide failed to show efficacy in a phase 3 sarcoma trial, shares of Ziopharm Oncology (TCRT -3.36%) fell through the floor, dropping by more than 66%. Do shareholders have any hope of a recovery? In this video, Motley Fool health-care analyst David Williamson takes us through what the cash situation looks like at Ziopharm, where the company will be shifting its focus next, and what, if any, hope remains.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Is Anything Left for Ziopharm Investors?
By Dave Williamson
–
Mar 26, 2013 at 7:37PM
NASDAQ: TCRT
Alaunos Therapeutics, Inc.
Market Cap
$10M
Today's Change
(-3.36%) -$0.17
Current Price
$4.89
Price as of July 3, 2025, 9:35 a.m. ET
Is there any hope for Ziopharm after this utter collapse?
David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Alaunos Therapeutics, Inc.
TCRT
$4.89
(-3.36%)
$0.17
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Alaunos Therapeutics Triumphed On Tuesday
Why Alaunos Therapeutics Stock Is Soaring Today
Why Alaunos Therapeutics Stock Sank Today
Why Alaunos Therapeutics Topped the Market on Tuesday
Why Alaunos Therapeutics Stock Is Up Yet Again Today
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.